Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-295 DDI Study with Oral Contraceptives in Healthy Overweight or Obese Women
NCT07414784Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Feb 2026
- Primary completion
- Aug 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GUB014295 in obesity, sponsored by AbbVie Inc. Primary endpoint: Number of Participants with Adverse Events at 128 days. Started Feb 2026; status: completed.
02
Drugs
GUB014295
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07414784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07414784.